Discounted Cash Flow Rating

Buy

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Sell

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Strong Buy

Standard Deviation

Strong Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Virios Therapeutics, Inc. Common Stock (VIRI)

Pharmaceutical Preparations

https://www.virios.com

Virios Therapeutics Inc is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia. The company is engaged in the development of its product, IMC-1, for people who are suffering from fibromyalgia.

44 MILTON AVENUE
ALPHARETTA, GA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

12/17/2020

Market Cap

5,274,001

Shares Outstanding

19,260,000

Weighted SO

19,257,937

Total Employees

N/A

Upcoming Earnings

08/08/2024

Similar Tickers

ICU --.--%

ZVSA --.--%

SONN --.--%

REVB --.--%

EFTR --.--%

ZURA --.--%

NAVB --.--%

IMMX --.--%

CNSP --.--%

Beta

1.6110

Last Div

0.0000

Range

0.156-1.37

Chg

0.0012

Avg Vol

1679079

Mkt Cap

5274001

Exch

NASDAQ

Country

US

Phone

866 620 8655

DCF Diff

0.0083

DCF

0.1767

Div Yield

0.0000

P/S

0.0000

EV Multiple

-0.4699

P/FV

1.3876

Div Yield %

0.0000

P/E

-0.9298

PEG

-0.0125

Payout

0.0000

Current Ratio

7.2707

Quick Ratio

7.2707

Cash Ratio

6.0395

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

0.0000

CCC

0.0000

Gross Margin

0.0000

Op Margin

0.0000

Pretax Margin

0.0000

Net Margin

0.0000

Eff Tax Rate

0.2721

ROA

-1.2870

ROE

-1.3035

ROCE

-1.5295

NI/EBT

1.0000

EBT/EBIT

0.9756

EBIT/Rev

0.0000

Debt Ratio

0.0000

D/E

0.0000

LT Debt/Cap

0.0000

Total Debt/Cap

0.0000

Int Coverage

-118.6537

CF/Debt

0.0000

Equity Multi

1.1595

Rec Turnover

0.0000

Pay Turnover

0.0000

Inv Turnover

0.0000

FA Turnover

0.0000

Asset Turnover

0.0000

OCF/Share

-0.1825

FCF/Share

-0.1825

Cash/Share

0.1319

OCF/Sales

0.0000

FCF/OCF

1.0000

CF Coverage

0.0000

ST Coverage

0.0000

CapEx Coverage

0.0000

Div&CapEx Cov

0.0000

P/BV

1.3876

P/B

1.3876

P/S

0.0000

P/E

-0.9298

P/FCF

-1.2621

P/OCF

-1.0412

P/CF

-1.0412

PEG

-0.0125

P/S

0.0000

EV Multiple

-0.4699

P/FV

1.3876

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jun 13, 05:30 Viridien conclut la vente d’un système de surveillance et d’alerte des navires, Marlin, auprès d’ExxonMobil Guyana Ltd GlobeNewswire Inc. Jun 13, 05:30 Viridien makes sale of Sercel Marlin vessel monitoring and alert system to ExxonMobil Guyana Ltd GlobeNewswire Inc. Jun 12, 05:30 Viridien awarded large seismic imaging project in Algeria by Groupement Berkine   GlobeNewswire Inc. Jun 12, 05:30 Viridien attributaire d’un important contrat d'imagerie sismique en Algérie GlobeNewswire Inc. Jun 11, 06:00 Viridien signe un accord avec Ranch Computing pour dynamiser le paysage des médias numériques GlobeNewswire Inc. Jun 11, 06:00 Viridien Joins Forces with Ranch Computing to Supercharge the Digital Media Landscape GlobeNewswire Inc. Jun 11, 05:30 Viridien wins 20 MUSD contract to supply a Sercel GPR300 OBN solution for North Sea project GlobeNewswire Inc. Jun 11, 05:30 Viridien remporte un contrat de 20 m$ pour la fourniture d'une solution OBN GPR300 Sercel en mer du Nord GlobeNewswire Inc. Jun 10, 05:30 Viridien launches new brand to accelerate growth as an advanced technology company GlobeNewswire Inc. Jun 10, 05:30 Viridien, leader dans les technologies de pointe, lance sa nouvelle marque et accélère sa croissance GlobeNewswire Inc. May 20, 00:53 Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study GlobeNewswire Inc. Feb 29, 14:15 Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results GlobeNewswire Inc. Feb 29, 14:15 Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

Revenue Product Segmentation